Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
AU |
|
Grindwell Norton Ltd
NSE:GRINDWELL
|
IN |
|
S
|
SCC Holdings Bhd
KLSE:SCC
|
MY |
|
N
|
NB Bancorp Inc
NASDAQ:NBBK
|
US |
|
Caleffi SpA
MIL:CLF
|
IT |
|
WASGAU Produktions & Handels AG
F:MSH
|
DE |
|
Nanoco Group PLC
LSE:NANO
|
UK |
|
A
|
Antiaging Quantum Living Inc
OTC:AAQL
|
US |
|
Itera ASA
OSE:ITERA
|
NO |
|
Cedar Woods Properties Ltd
ASX:CWP
|
AU |
|
Pharmicell Co Ltd
KRX:005690
|
KR |
|
GoTo Gojek Tokopedia PT Tbk
IDX:GOTO
|
ID |
|
Experience Co Ltd
ASX:EXP
|
AU |
|
U
|
Uniqa Insurance Group AG
VSE:UQA
|
AT |
|
SUI Group Holdings Ltd
NASDAQ:SUIG
|
US |
|
A
|
ABx Group Ltd
ASX:ABX
|
AU |
|
S&T Bancorp Inc
NASDAQ:STBA
|
US |
|
Credit Corp Group Ltd
ASX:CCP
|
AU |
Wall Street
Price Targets
PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
PAR
is 0.66 AUD
with a low forecast of 0.66 AUD and a high forecast of 0.68 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PAR's stock price target?
Price Target
0.66
AUD
According to Wall Street analysts, the average 1-year price target for
PAR
is 0.66 AUD
with a low forecast of 0.66 AUD and a high forecast of 0.68 AUD.
What is Paradigm Biopharmaceuticals Ltd's Revenue forecast?
Projected CAGR
185%
For the last 10 years the
compound annual growth rate for
Paradigm Biopharmaceuticals Ltd's revenue is
99%.
The projected
CAGR
for the next 3 years is
185%.
